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ABSTRACT: Adrenomedullin (AM) is a recently 
discovered pluripotent peptide initially isolated from a 
human adrenal gland tumor (pheochromocytoma). 
Adrenomedullin has been shown to have an ancient 
origin with immunoreactive species found in mam- 
mals, birds, reptiles, amphibians, fish, and echino- 
derms (starfish). Given its highly conserved evolu- 
tionary expression, AM is thought to  play a critical 
role in species survival. This peptide has been shown 
to mediate a variety of physiological functions, of 
which its involvement in growth regulation will be the 
central focus of this paper. In the following text, we 
will review the cited literature in this area and 
include our own observations regarding AM expres- 
sion in carcinogenesis, embryogenesis, and wound 
repair. Adrenomedullin will be shown to induce both 
growth promotion or growth suppression depending on 
the target cell examined and the surrounding nutri- 
tional environment in which the analysis was done. Its 
implied role as a mitogen, angiogenic factor, and 
apoptosis survival factor will be critiqued and evalu- 
ated relative to its importance in the cell proliferation 
process. Finally, we will review the antimicrobial 
effect AM has on several human pathogens ( E s -  
cherichia coli and Candida albicans) and demonstrate 
its participation in the host immune response system 
as a first line defense peptide. 
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Introduction 
Adrenomedullin ( AM) was initially identified as a 
chromatographic isolate from the acid extract of 
human pheochromocytoma tissue that was capable of 
elevating platelet cyclic adenosinemonophosphate 
(CAMP) and inducing a hypotensive effect in ex- 
perimental rats (Kitamura et al., 1993a). The cDNA 
base sequence for mouse, rat, pig, cow, dog (partial 
sequence), and human message have been determined 
and the molecular organization of human and mouse 
genes identified (Kitamura et al., 1993b, 1994; Sakata 
et al., 1993; Ishimitsu et al., 1994; Okazaki et al., 
1996; Barker et al., 1998; Jougasaki, 1998). Figure 1 
is a schematic diagram that illustrates the transcrip- 
tion and translation products of human AM. For a 
more detailed description of the human AM informa- 
tion present in this figure, refer to  accession number 
D43639 (gene) or D14874 (mRNA) in the GenBank 
web page. The AM message is composed of four exons 
and three introns; however, exon one is not read and 
only part of exon two, all of exon three and part of 
exon four are translated into the prepro AM precursor 
molecule. Several transcription factor response ele- 
ments have been identified in the 5' flanking region of 
the human AM gene, which include AP-1, AP-2 and y- 
IRE sites as well as CRE and SSRE sites in the first 
intron (Ishimitsu et al., 1994; Minamino et al., 1998). 
Interestingly, it has been shown that basal expression 'To whom correspondence should be addressed: Intervention 
Section, Dept. of Cell and Cancer Biology, Medicine Branch, of AM in human Wdothelial cells requires a 
Building 10, Room 12N226, Bethesda. MD 20892, Tel.: minimum Of 110 bp at the 5' flanking region of the - -
301-4023308; Fax: 301-435-8036; E-mail: cuttittaf@bprb.nci.nih.gov first exon (Ishimitsu et al., 1998). Northern analvsis 
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Figure 1. The sequential molecular products (gene/ 
mRNA/protein) of human adrenomedullin (hAM). The 
gene for hAM (accession no. D43639) encodes four exons 
and three introns with a 5' promoter region which 
contains AP-I, AP-2 and ./-IRE sites (Ishimitsu et al., 
1994; Minamino et al., 1998). The hAM message 
(accession no. D14874) is 1.6 kb in size and is translated 
into a 185 amino acid precursor protein that contains 
two active peptides, AM and PAMP (Kitamura et al., 
1993b; Cuttitta et al., 1998). 
al., 1998). Parallel findings of AM protein expression 
in these tissues have been demonstrated by RIA and 
immunohistochemical analysis (Ichiki et al., 1994; 
Sakata et al., 1994; Montuenga et al., 1997). 
Adrenomedullin shares structural homology with cal- 
citonin gene-related peptide ( CGRP) and amylin 
(Kitamura et al., 1998). 
Adrenomedullin or AM-like proteins have been 
detected in both vertebrate (mammals, birds, reptiles, 
amphibians , fish) and nonvertebrate (echinoderms ) 
species; therefore representing a highly conserved 
peptide throughout the evolutionary progression of 
animals (L6pez Diez Del Corral and Cuesta Rubio, 
1998). Because of its repetitious expression in the 
animal kingdom, which dates back 100 million yr  or 
more, AM has been implicated to play some fun- 
damental role in species survival (Cuttitta et al., 
1998). This idea has been further substantiated by 
the fact that AM has been shown to operate as a 
pluripotent peptide that modulates a variety of 
physiological functions which include: cardiovascular 
tone (Ishiyama et al., 1993; Nuki et al., 1993; Lippton 
et al., 1994; Santiago et al., 1994; Fukuhara et al., 
1995; Parkes, 1995), central brain activity (Taka- 
hashi et al., 1994; Murphy and Samson, 1995; 
Martinez et al., 1997c; Samson and Murphy, 1997), 
bronchodilation (Kanazawa et al., 19941, hormone 
release (Yamaguchi et al., 1995; Samson et al., 1995; 
Martinez et al., 1996b, 1998), renal output (Ebara et 
al., 1994; Jougasaki et al., 1995; Majid et al., 19961, 
apoptosis (Kato et al., 19971, angiogenesis (Zhao et 
al., 19981, cell growth (Miller et al., 1998), and 
immune response (Walsh et al., 1996, 1998; Kubo et 
al., 1998 a,b; Zaks-Zilberman et al., 1998). In the 
following text, we will focus on the growth regulatory 
role that AM plays on cell proliferation, growth 
cessation, differentiation, embryogenesis, carcinogene- 
sis, immune response, and wound repair. A summary 
of these findings are presented in Table 1. 
Adrenomedullin-Induced Growth Stimulation 
The first demonstration of the ability of AM to 
stimulate cell growth came from a collaborative study 
between the Imperial Cancer Research Fund and the 
Imperial College School of Medicine at the Hammer- 
smith Hospital in London, England. These two groups 
reported that AM induces a dose-dependent increase 
in t3H]-thymidine incorporation and elevates the 
number of confluent quiescent Swiss 3T3 mouse 
fibroblast cells cultured under serum-free conditions 
(Withers et al., 1996). The AM response was aug- 
mented synergistically when insulin was added to  the 
cell culture media. These investigators found that AM 
caused an increase in the intracellular CAMP levels of 
Swiss 3T3 cells, which was both time and concentra- 
tion dependent, but had no effect on Ca2+ mobilization. 
Adrenomedullin had previously been shown to acti- 
vate Ca2+ mobilization as an alternative signal 
transduction pathway in bovine aortic endothelial 
cells (Shimekake et al., 1995). In the Swiss 3T3 
model, AM induction of CAMP accumulation was not 
accompanied by the activation of protein kinase C 
(PKC) or phospholipase C (PLC), because there was 
no observed increase in tyrosine phosphorylation of 
intracellular substrates or alteration in the production 
of inositol phosphates. The protein kinase A inhibitor 
H-89 blocked AM induced labeled nucleotide uptake 
but had no effect on epidermal growth factor driven 
[3Hl-thymidine incorporation ( a non CAMP-dependent 
process). A Swiss 3T3 cell line that was stably 
transfected with a constitutively activated Gsa 
subunit, [Gsa9Q227Las03T3], expressed a 250-fold 
increase in sensitivity to AM regulated pH] -thymidine 
incorporation over the wild-type parent with resulting 
EC50 of 4 pM and 1 nM respectively. Finally, with the 
use of [1251]-AM and [12511-CGRP labels, it was 
determined that Swiss 3T3 cells selectively bind AM 
and that this receptodigand interaction was not 
disrupted with cold CGRP or CGRP8-37 (CGRP 
antagonist) at concentrations up to 1 pM. These 
seminal studies by Withers and coworkers were 
subsequently confirmed 2 yr later by an independent 
laboratory that identified a putative AM mediated 
autocrine growth circuit in Swiss 3T3 cells (Isumi et 
al., 1998a). 
Our laboratory has completed a detailed analysis of 
MAM-receptor ( AM-R) expression in the normal/ 
malignant human lung, determined the subset of cells 
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involved, and identified a possible autocrine growth 
mechanism of the airway (Martinez et al., 1995, 
1997b; Miller et al., 1996, 1998). In our initial studies, 
we demonstrated that a variety of specialized pulmo- 
nary cells expressed AM mRNA/protein. These in- 
cluded ciliatednonciliated epithelium, endothelial 
cells of the vascular bed, smooth muscle cells sur- 
rounding the bronchus, chondrocytes, neurons of the 
parasympathetic nervous system, and activated alveo- 
lar macrophages (Martinez et al., 1995). When 
examining archival specimens by immunohistochemis- 
try, we found that many pulmonary malignancies 
derived from the airway epithelium also expressed 
high levels of AM immunoreactivity (adenocarcino- 
mas, large cells carcinomas, squamous cell carcino- 
mas, and carcinoids) with the exception of small cell 
carcinomas, which routinely showed a low staining 
phenotype (Martinez et al., 1995). Similar results 
were also observed for representative human tumor 
cell lines of the lung when AM immunoreactivity or 
AM message were evaluated (Martinez et al., 1995). 
In addition, we have shown that several other human 
tumor cell lines of diverse tissue origin also have 
elevated AM expression, including cancers of the 
colon, breast, ovary, prostate, brain, cartilage, adrenal 
gland, blood and skin (Miller et al., 1996, 1998; 
Martinez et al., 1997a). The vast majority of the 
above-mentioned cell lines have been shown to express 
the AM-R message by RT-PCR, thus implicating a 
potential autocrine growth relationship (Miller et al., 
1996; Martinez et al., 1997a). In support of this 
theory, we have used a neutralizing anti-AM 
monoclonal antibody (MoAb-G6) to  block the cell 
proliferative effects of endogenous AM in lung, breast, 
and ovary cancer cell lines (Miller et al., 1996). The 
growth suppressive effects of MoAb-G6 could be 
inhibited by the addition of synthetic AM, resulting in 
the restoration of cell proliferation (Miller et al., 
1996). Using a human breast carcinoma cell line 
(MCF-7) as a model, it was shown that this cancer 
cell produced and released authentic AM into the 
conditioned medium when grown in a serum-free 
environment and selectively bound [1251]-AM at high 
affinity ( K d  = 4 nM) with a calculated receptor 
density of 50,000 sites per cell (Miller et al., 1996). In 
addition, exogenous AM induced a dose-dependent 
Table 1. Adrenomedullin mediated regulation of cell growth 
Signal transduction 
pathway or 
Test cell type Growth effect mechanism of action1 Reference 
Mouse fibroblast cell line 
Rat fibroblast cell line 
Human neuroblastoma cell line 
Human oral keratinocytes cell line 
Human skin melanoma cell line 
Human breast carcinoma cell line 
Human ovarian carcinoma cell line 
Human lung adendsquamous carcinoma 
Human lung carcinoid cell line 
Human umbilical vein endothelial cells 
Rat endothelial cells 
cell line 
Rat mesangial cells 
Rat vascular smooth muscle cells 
Fetal rat osteoblast 
In vitro cultures of human cytotrophoblast 
Fetal cells during mousehathuman 
embryogenesis 
Mouse mammary gland development 
Chick chorioallantoic membrane 
Repair of salt/ethanol induced damage of 
Escherichia coli and Candida albicans 
(neovasculature) 


















Proliferation and differentiation 
Proliferation and differentiation 
Stimulation (angiogenic factor) 
Stimulation (promoter of wound 

























Withers e t  al., 1996 
Wang et al., 1996a,b 
Ando et al., 1997 
Kapas et al., 1997 
Martinez et al., 1997a 
Miller et al., 1996 
Miller et al., 1996 
Miller et al., 1996 
Miller et al., 1996 
Zhao et al., 1998 
Nitchibata et al., 1998 
Kat0 et al., 1997 
Chini et al., 1995 
Segawa et  al., 1996 
Nitchibata et al., 1998 
Kano et  al., 1996 
Iwasaki et al., 1998 
Cornish et  al., 1997 
Morrish et al., 1996 
Montuenga et  al., 1997 
Macri e t  al., 1996 
Di Iorio et al., 1997 
Jahnke et  ai., 1997 
Zhao et al., 1998 
Fukuda et  al., 1998 
Walsh et al., 1996, 1998 
'CAMP = cyclic adenosine monophosphate; ND = not determined; MAPK = mitogen-activated protein kinase. 
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increase in the intracellular cAMP of MCF-7 that 
could be blocked by MoAb-G6 (Miller et al., 1996). 
Our collective results strongly suggest that AM may 
function as an autocrine growth factor for certain 
human tumors and that it represents an interesting 
target to  evaluate in intervention strategies for the 
possible disruption of carcinogenesis. 
The skin has also been shown to be an anatomical 
site with extremely high AM transcriptiodtranslation 
product expression (Martinez et al., 1997a). Cells of 
the integument and their underlying specialized 
epidermal structures (hair follicles and sweat glands 
[eccrine or apocrine]) were areas of abundant AM 
production. In fact, AM levels in sweat were shown to 
be fivefold higher than concentrations found in the 
blood with respective mean values of 87.9 and 16.8 
fmol/mL. The labeled ligand [1251]-AM selectively 
bound normal and malignant human skin cell lines 
with a & of approximately 9 nM and was not 
significantly displaced by AM22-52, CGRP, CGRP8-37 
or amylin at 1 p M  concentration. Exogenous AM 
increased the proliferative index of a human mela- 
noma cell line, cultured under 5% FCS, in a dose- 
dependent manner that approached the growth rate 
achieved in 10% FCS. In similar studies using a 
human oral squamous cell carcinoma line (H357), 
Kapas et al. (1997) have also demonstrated a 
mitogenic role of AM in cells having a keratinocyte 
lineage. They reported that AM elevated intracellular 
levels of CAMP in H357 with a significant inflection at 
10 pmoVL and a maximal fourfold response achieved 
at 10 nmoVL. In addition, using H357 as the target 
cell for [12511 -AM binding studies, these investigators 
have identified a single population of receptors with a 
calculated & of 8.25 nmom and a B, of 466 fmoV 
mg protein. Cold CGRPI, CGRPII, CGRP8-37, and 
amylin were ineffective in displacing the [12511-AM 
label at  concentrations exceeding 950 nmol/L. H357 
growth induction by exogenous AM, as measured by 
[3Hl -thymidine uptake, paralleled the cAMP response 
graph with a measurable proliferation increase (25% 
over untreated control, P c .05) with as little as 10 
pmol/L of the peptide. The CAMP homolog, dibutyryl 
CAMP, also caused significant increases in the growth 
rate of H357 (twofold elevation), which suggested 
that AM induced proliferation involved a CAMP- 
dependent mechanism. Interestingly, neither the PKC 
inhibitor, Ro31-8220, nor the tyrosine kinase inhibi- 
tor, lavendustin A, had an effect on AM mediated 
growth of H357. 
Recent studies by Cornish et al. (1997) have 
demonstrated that AM can stimulate the growth of 
rodent osteoblasts in vitro and in vivo (Cornish et al., 
1997). At concentrations of M and greater, AM 
produced a dose-dependent increase in cell number 
and [3Hl -thymidine incorporation in primary cultures 
of fetal rat osteoblasts. Peptide fragments of Ah4 
(AM 15-32, AM22-52, and AM27-52) with truncated 
amino terminal end (with or without disulfide loop) 
were capable of inducing growth. These investigators 
have also demonstrated that amyling-37 ( an  arnylin 
antagonist) could effectively block AM stimulated cell 
proliferation of fetal rat osteoblasts, thus indicating 
that AM mediated growth effects are regulated 
through the amylin receptor. When applying similar 
investigative studies to bone organ cultures of neona- 
tal mouse calvaria that had been prelabeled in vivo 
with 45Ca, AM was shown to increase both DNA and 
protein synthesis without affecting basal bone resorpt- 
ing rates (release rate of 45Ca remained constant). 
Finally, local administration of AM to the skullcap of 
adult mice caused a threefold increase in the index of 
osteoblast activity in treated hemicalvaria compared 
to the untreated control side and also increased 
mineralization of the bone in this region. 
While investigating tamoxifen ( Txf) induced en- 
dometrial hyperplasia in premenopausal women, Zhao 
et al. (1998) demonstrated, using PCR differential 
display, that this nonsteroidal antiestrogen stimulated 
AM message expression in normal human endometrial 
stromal cells. Based on these data, these investigators 
began to evaluate the possibility that AM may 
underlie Txf induced endometrial hyperplasia. Toward 
this end, Zhou et al. (1998) examined the mitogenic 
effects of AM on primary cultures of human umbilical 
vein endothelial cells (KUVEC) grown in the 
presence of 10% FCS. Adrenomedullin (10 nM) was 
shown to give a comparable growth promoting 
response as basic fibroblast growth factor ( a t  similar 
molar concentration) on cultured HUVEC resulting in 
a twofold increase in the proliferative index over a 6 d 
evaluation period. In addition, AM was demonstrated 
to  be an angiogenic factor in a chick chorioallantoic 
membrane assay, which caused significant increases 
in neovascularization ( P  < .005 to P < .05) over the 
dose range of 10 pM to 1 nM. The mitogenic features 
and angiogenic capability of AM have been implicated 
by Zhao et al. (1998) as a possible autocrindparacrine 
mechanism regulating Txf induced endometrial polyp 
formation or uterine neoplasia expression. 
In a recent seminal report by Iwasaki et al. (19981, 
AM was identified as a growth-promoting factor for 
primary cultures of rat vascular smooth muscle cells 
( VSMC) grown under serum-free conditions. 
Adrenomedullin was shown to increase DNA synthesis 
and cell number of quiescent VSMC over a test 
concentration of 1 nM to 1 pM. CGRP gave a similar 
but less potent growth response when evaluated at the 
same concentration range. The peptide antagonist 
CGRP8-37 suppressed the growth stimulatory effects of 
both AM and CGRP on quiescent VSMC targets 
implicating the involvement of a common receptor. 
The activity of p42Ip44 mitogen-activated protein 
kinase ( IMAPK), a member of the serindthreonine 
kinases family, in quiescent VSMC was upregulated in 
a dose-dependent and time-dependent manner by AM. 
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Adrenomedullin induced activation of MAPK was not 
affected by 8-bromo-CAMP, forskolin, a CAMP an- 
tagonist (Rp-CAMP-thionate), nor by the PKA inhibi- 
tor (KT5720), thus appearing to involve a CAMP- 
independent regulatory mechanism. In addition, AM 
was shown not to  invoke a Ca2+ mobilization response 
nor alter inositol phosphate levels in VSMC, and the 
PKC inhibitor (GF109203) did not block Ah4 induced 
MAPK activation. These data suggest that AM medi- 
ated growth of quiescent VSMC is not controlled 
throslgh PKC or PLC pathways. Interestingly, the 
growth-promoting effects of AM were accompanied by 
the transactivation of the early response gene c-fos. In 
order to dissect crucial areas of the MAPK cascade 
required for AM modulation of VSMC growth, these 
investigators used the MAPK kinase ( MEK) inhibitor 
PD98059 which blocked AM activation of MAPK, 
suppressed AM induction of c-fos expression and 
muted AM growth stimulation of the target cell. Along 
similar lines, it was found that the protein tyrosine 
kinqse ( PTK) inhibitor genistein or ST630 completely 
blocked AM induced MAPK activation and suppressed 
the proliferative effects of AM on VSMC, thereby 
identifying a previously unknown pathway by which 
AM regulates cell growth. One of the most interesting 
findings to  emerge from this study was that AM could 
have diametrically opposed growth effects in the same 
model system depending on the environmental condi- 
tions. As will be discussed in the next section, AM has 
been previously shown by Kano et al. (1996) to 
inhibit the growth of rat VSMC under serum sup- 
plemented conditions, whereas the work of Iwasaki et 
al. (1998) demonstrates the opposite effect, in which 
AM mediates growth-promotion in rat VSMC cultured 
in the absence of serum. 
Adrenomedullin-Mediated 
Growth Suppression 
In the previous section, we reviewed the reported 
literature in support of AM as a mitogenic factor 
capable of driving cell growth in a variety of mam- 
malian cell systems; we will now present the paradoxi- 
cal side of this pluripotent peptide, which implicates 
AM as a growth cessation factor. The first report to  
clearly demonstrate a growth suppressive effect for 
AM was authored by Chini et al. (19951, who 
evaluated the peptide in a primary culture of rat 
mesangial cells ( rMC). Previously, these investiga- 
tors had shown that elevations in intracellular CAMP 
could block the basal or mitogen-induced growth of 
rMC (Matousovic et al., 1995). Applying a similar 
experimental strategy to study AM-mediated growth 
effects on rat kidney reticuloendothelial cells, these 
investigators showed that the peptide, through “nega- 
tive crosstalk”, inhibited the W K  signal transduc- 
tion cascade, thereby suppressing cell proliferation 
(Chini et al., 1995). At a dose range of 1 to 100 nM, 
AM was shown to activate CAMP-dependent protein 
kinase A (PKA), which, in turn, could potentially 
phosphorylate the regulatory domain of Raf-1 (Chini 
et al., 1995; Wu et al., 1995). Prior studies in this area 
had revealed that phosphorylation of the catalytic 
domain of Raf-1 caused the inhibition of its protein 
kinase activity, thereby blocking MAPK and resulting 
in the suppression of mitogen-induced growth (Graves 
et al., 1993; Marx, 1993; Sevetson et al., 1993; Cook 
and McCormick, 1993; Wu et al., 1995). Adrenomedul- 
lin blockade of rMC growth has been proposed by 
Chini et al. (1995) to  involve a similar Raf-1 
dependent mechanism. Expanding this initial study, 
Chini and coworkers (Chini et al., 1996) have shown 
that AM does not inhibit all types of mitogen-induced 
growth. Interestingly, even though AM will suppress 
platelet-derived growth factor ( PDGF) and epidermal 
growth factor ( EGF) mediated proliferation of rMC, it 
does not inhibit endothelin-1 ( ET-1) induced growth. 
Although all three cytokines activate MAPK, the 
selective AM inhibition of mitogen-induced mesangial 
cell growth is thought to involve different isomers of 
Raf-1. Ventricular myocytes have been previously 
shown by Bogoyevitch et al. (1995) to  contain two 
isoforms of Raf, denoted as c-Raf ( o r  Raf-1) and A- 
Raf, ,which were differentially regulated by fibroblast 
growth factor ( FGF) (c-Raf activation) and ET-1 (c- 
Raf and A-Raf activation). Although PKA could 
inhibit c-Raf activity, it was far less effective in 
inhibiting A-Raf activation (Bogoyevitch et al., 1995). 
Chini et al. (1996) have used this relationship of 
different isoforms of Raf to explain their data on 
selective AM inhibition of mitogen-induced rMC 
growth. They propose that PDGFEGF utilize the c- 
Raf isoform similar to FGF (blocked by AM/PKA), 
whereas in the case of ET-1, although c-Raf is 
activated (AM/PKA suppressive isoform), it is the 
PKA resistant isoform A-Raf that drives MAPK 
activation in the presence of AM (Chini et al., 1996). 
A recent report from Shiga University of Medical 
Science is in direct conflict with the observations of 
Chini, given that this group has demonstrated the 
ability of AM to inhibit ET-1 induced MAPK activity 
in rMC (Haneda et al., 1996). As a final note to these 
types of studies, it has been shown by Segawa et al. 
(1996) that AM can suppress serum induced growth 
of rMC through a CAMP-dependent pathway. 
We have previously discussed the proliferative 
action that AM can convey to rat VSMC (ending 
paragraph of the prior section) and will now review its 
growth suppressive effect in this same cell system. 
There have been several reports in the literature 
which demonstrate AM-R expression in VSMC 
(Eguchi et al., 1994a,b; Ishizaka et al., 1994). Kano et 
al. (1996) have found that exogenous AM can block 
the trophic effects of serum on VSMC in a time/ 
concentration dependent manner by elevating in- 
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tracellular CAMP levels. At a post-treatment time 
point of 24 h, AM ( 1 0-7 mol/L) caused an approximate 
50% reduction in the serum induced growth of rat 
VSMC as assessed by thymidine incorporation. For- 
skolin and 8-Br-CAMP were shown to mimic the 
inhibitory response of AM on serum driven growth in 
VSMC. The growth suppressive effects of AM on rat 
VSMC was abolished by the CGRP antagonist 
(CGRPg-37), implying that a common receptor medi- 
ated the peptide induced inhibition of serum promoted 
cell proliferation. This result is consistent with the 
data of Ishizaka et al. (19941, who reported that 
CGRPg-37 could block AM mediated increases in 
intracellular CAMP for rat VSMC. Interestingly, AM 
has been shown to induce GO to  G1 cell cycle 
progression in synchronized VSMC, which is as- 
sociated with the induction of c-fos and AP-1 activa- 
tion, events normally attributed to cell growth but also 
known to involve growth suppression via differentia- 
tion (Kobayashi et al., 1995; Sat0 and Autelitano, 
1995). The ability of AM to trigger early response 
gene c-fos mRNA expression in VSMC was inhibited 
by the PKA blocker analogue H-89, which is in line 
with previously discussed data by Chini et al. (see 
above) (Chini et al., 1995; Sat0 and Autelitano, 
1995). 
Early in the developing field of AM studies, it was 
reported that vascular endothelial cells ( VEC) 
produced AM mRNA and actively secreted authentic 
peptide (Sugo et al., 1994a). This discovery was 
shortly followed by an article by Kat0 et al. (1995) 
describing AM binding sites being present on human 
VEC. When AM was added to cultures of human VEC 
at concentrations of 10-10 to 10-6 M, an exponential 
increase in intracellular CAMP was noted. CGRP was 
also shown to increase CAMP in this cell system but at 
a molar potency that was lOOOx less than that 
observed for AM. Interestingly, CGRPg-37 could sig- 
nificantly block, at equimolar concentrations, the 
CGRP mediated increase in CAMP but was unable to  
affect AM induced elevation of CAMP. These data 
suggested the existence of two independent receptors, 
one of which was specific for AM and the other having 
a preference for CGRP. Thus, the combined AM data 
presented thus far implicates the possibility of an 
autocrine/paracrine mechanism functioning in human 
VEC. Several recent findings have confirmed this 
hypothesis. Isumi et al. (1998b) have shown that 
certain proinflammatory cytokines [tumor necrosis 
factor ( TNF)-a  and interleukin ( IL)-11 can signifi- 
cantly increase ( P  < .O 1) AM production in rat VEC 
whereas TGF-/3 suppresses AM synthesis in these 
cells. This finding suggests that during bacterial 
infection (sepsis), the VEC may play a role in 
regulating homeostasis of vascular tone. Work by 
Michibata et al. (1995, 1996, 19981, using a neutraliz- 
ing anti-AM monoclonal antibody, has determined 
that immuno-blockade of endogenous AM caused basal 
CAMP levels to  decrease and DNA synthesis to 
increase in VEC, VSMC, and MC, thus implicating an 
autocrine/paracrine growth regulatory role for AM in 
all three cell types. 
Adrenomedullin in Embryogenesis, 
Organogenesis, and Differentiation 
Initial studies from our group demonstrated spatio- 
temporal M A M - R  expression during mouse and rat 
embryogenesis (Montuenga et al., 1997). Immuno- 
histochemistry and in situ hybridization confirmed 
colocalization of AM transcriptionaVtranslationa1 
products at distinct anatomical sites. The developing 
heart was the first organ to express abundant 
amounts of AM at embryonic day ( E )  8 followed by 
the neovasculature, brain, spinal corddorsal root 
ganglia, lung, skin, liver, intestine, and kidney (E10 
to E14). Interestingly, there were specialized areas of 
cellular development at  sensory sites that also showed 
high AM expression that included the cochlear 
epithelium of the ear (E 121, nasal epithelium (E12), 
hair follicle (E 13 1, and retina (E 15 ) . Noted through- 
out the organogenesis process was the fact that as 
undifferentiated mesenchymal cells begin to  coalesce/ 
condense into distinctive specialized cell structures 
M A M - R  expression in that area increases. As the 
differentiatiodmaturation process continues, the level 
of AM production increases to a maximum and then 
progressively decreases to concentrations observed in 
neonate/adult tissue. Dramatic changes in the AM 
levels a t  a given anatomical site can take place in a 
matter of days. Take for example, the maturation 
process of the dorsal root ganglia, where, at E l l ,  only 
the neural prolongations express detectable AM, by 
E12 several neurons of the ganglion itself begin to  
show AM production, and by E14 the entire structure 
develops intense staining for AM. Similar data have 
been observed in the formation of the cartilaginous 
templates that precede bone: the more mature chon- 
drocytes (hypertrophic cells) have elevated AM/AM-R 
expression whereas the newly formed chondrocytes 
have almost undetectable levels. In these previously 
discussed tissue sites there appears to  be a direct 
correlation between M A M - R  expression and the 
growtWdifferentiation processes observed during em- 
bryogenesis. 
Early in embryogenesis ( E 9 )  high levels of AM/AM- 
R were expressed at the ectoplacental cone, site of 
implantation, where fetal trophoblastic giant cells 
interact with maternal decidual cells. Neovasculariza- 
tion occurs at  this area to  establish the placental 
capillary bed, which supplies nutritional sustenance 
for the developing fetus. Because AM has been 
reported to be a mitogenic factor and an angiogenic 
factor (Withers et al., 1996; Zhao et al., 19981, the 
ectoplacental cone would be an obvious anatomical 
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site for elevated W A M - R  expression. Interestingly, 
recent studies by Morrish et al. (1996) have indicated 
that AM may be an early genetic marker for epidermal 
growth factor ( EGF) induced in vitro differentiation 
of human cytotrophoblasts. Previously, it had been 
shown that human placental cytotrophoblasts 
differentiate by fusion to form a multinucleated 
syncytium and that this process could be mimicked in 
vitro in a cytotrophoblast culture system (Gerbie et 
al., 1968; Morrish et al., 1987). Morrish et al. (1987) 
had previously demonstrated that EGF could stimu- 
late giant cell formation (differentiation) in cultured 
human cytotrophoblasts. An evaluation by subtractive 
hybridization of EGF treated vs untreated 
cytotrophoblasts (freshly isolated from human 
placenta) showed that in vitro induction of differentia- 
tion accompanied elevations in AM mRNA expression 
(Morrish et al., 1996). 
There are several aspects of the implantation 
process that parallel the events associated with tumor 
cell invasion into the substroma matrix during car- 
cinogenesis (Yagel et al., 1988; Graham and Lala, 
1991). Implantation involves two key progressional 
steps: 1) migratiodintercalation of the fetal trophob- 
last into the maternal tissue through the action of 
plasminogen activators and matrix metalloproteases 
(Ray and Stetler-Stevenson, 1994; Harvey et al., 
1995); and 2)  neovascularization induced by a variety 
of angiogenic factors, such as vascular endothelial 
growth factor ( VEGF) , transforming growth factor- 
P(TGF-@) and AM, to accommodate nutritional sup- 
port and waste removal for the developing fetus 
(Roberts et al., 1986; Ryan et al., 1998; Zhao et al., 
1998). Both of these steps have also been shown to 
play a critical role in the tumor invasion process (Ray 
and Stetler-Stevenson, 1994; Harvey et al., 1995; 
Roberts et al., 1986; Ryan et al., 1998; Zhao et al., 
1998). Interestingly, we have recently demonstrated 
the coordinate expression of TGF-01 and AM during 
rodent embryogenesis, in particular at the ectoplacen- 
tal cone, which may reflect concomitant involvement 
of these two peptides in growtldangiogenesisldifferen- 
tiation pathways (Montuenga et al., 1998). 
We have identified AM expression in second- 
trimester human amniotic fluid and amniotic mem- 
branes, suggesting that this peptide may be involved 
in the maintenance of normal pregnancy (Macri et al., 
1996a). Similar findings have been observed for the 
maternal decidual cells in the first trimester (Macri et 
al., 199613). These data are consistent with the 
findings of Di Iorio et al. (1997, 1998), who demon- 
strate elevated AM plasma levels in pregnant women 
when compared to nonpregnant controls, and who 
have observed a dramatic diminution in AM plasma 
concentration (50% reduction) 48 h postpartum. 
Almost identical findings, regarding AM plasma level 
fluctuations, have been reported for pregnant rats 
(Kaufman et al., 1998). Interestingly, AM has also 
been implicated in preeclampsia syndrome; however, 
there is still controversy over whether low plasma 
levels of this peptide in the mother directly initiate 
this condition or high levels reflect a maternal 
compensatory response (Lauria et al., 1996a,b; Hata 
et al., 1997; Di Iorio et al., 1998). 
Finally, taking a more global look at AM in the 
female reproductive tract and in mammary gland 
development, it  is becoming increasingly clear that 
this peptide must play a critical role in the physiology 
of these tissues (Jahnke et al., 1996, 1997; Macri et 
al., 1998). Jahnke et al. have demonstrated that in 
the sexually immature mouse, the vaginal epithelium 
is devoid of AM expression. However, after estrogen 
treatment, a time-dependent increase in AM (mRNA 
and protein) was noted in the vagina, which was 
observed as early as 6 h and maintained for 48 h 
(Jahnke et al., 1996). Similar estrogen induced 
increases in AM levels were also noted in the uterus 
and myometrium. This same group has done an 
extensive immunohistochemicallin situ hybridization/ 
Northern blot study on AM in the human female 
reproductive tract (ectocervix, endocervix, en- 
dometrium, myometrium, ovary, and fallopian tube), 
which strongly suggests a menstrual phase depen- 
dency of expression (Macri et al., 1998). These 
investigators have demonstrated not only shifts in 
staining intensity of AM but also alterations in 
intracellular localization being dependent on cyclic 
regulation. In general, throughout the reproductive 
tract highly intense cytoplasmic immunostaining for 
AM was observed during the proliferative phase, 
which drops off dramatically during the secretory 
phase and translocates to  the nucleus. These data, in 
combination with findings from other laboratories 
(Jahnke et al., 19961, support hormonal control of AM 
expression in the female reproductive tract and given 
the cytoplasmic/nuclear translocation shifts observed 
implicate a possible role for AM as a transcription 
factor in gene regulation (Macri et al., 1998). The 
developing mammary glands are also known to be 
under hormonal control during the sexual maturation 
process. Jahnke and coworkers have examined AMI 
AM-R in mouse mammary gland and reported an 
estrogen dependent increase in message expression in 
that tissue (Jahnke et al., 1997). During the second 
third of embryo development (E 141, AM mRNA levels 
drop compared to amounts observed for 15-mo virgins 
and the AM-R message remains constant with virgin 
controls; however, AM levels rapidly rise by the 18th d 
of lactation. In addition, when evaluating hormonal 
control of W A M - R  expression in the mammary gland 
of ovariectomized mice, it was shown that estrogen 
treatment enhanced expression, progesterone had 
little effect, but a combination of estrogedprogester- 
one caused a synergistic elevation in AM message 
(Jahnke et al., 1997). Immunohistochemical and in 
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situ RT-PCR analysis detected AM in the luminal 
epithelium of small and large ducts and in terminal 
end buds. Highest intensity staining was observed 
during lactation, where the epithelium of inflated 
ducts and the milk itself expressed positive im- 
munoreactivity. When the milk was examined by 
polyacrylamide gel electrophoresis followed by im- 
munoblotting, authentic AM (6,000 MW) was identi- 
fied. Given that AM can regulate growth, control gut 
function (Martinez et al., 1 9 9 7 ~ )  and assert a 
protective role against microbial pathogens (see 
subsequent section on AM as an antimicrobial pep- 
tide), its importance in mother’s milk seems directly 
related to a beneficial support mechanism for the 
neonate. 
Adrenomedullin in Apoptosis 
An extremely interesting finding by Kat0 et al. 
(1997) is the autocrine/paracrine role that AM plays 
as an apoptosis survival factor for rat aortic en- 
dothelial cells ( rEC) cultured under serum-free 
conditions. These investigators showed that both 
endogenous and exogenous AM protected rEC from 
apoptosis induced by serum deprivation. Under the 
harsh growth conditions of a serum-free environment, 
approximately 40% of the seeded rEC undergo apopto- 
sis as determined by counting detached cell population 
via Coulter Counter, detecting cells with single 
stranded DNA staining ( SSDS) and measuring 
nucleosomal ladder formation ( NLF) . Exogenous AM 
suppressed apoptosis in a concentration- and time- 
dependent manner. A linear protection effect was seen 
over an AM dose range of to lop6 M ,  with a 50% 
reduction in apoptosis observed at  1 pM ( P  < .Ol), 
dramatically decreasing SSDS and diminishing NLF. 
The AM apoptosis survival effect was shown not to 
involve CAMP, Ca2+ mobilization, or PI turnover. In 
addition, this protective effect was not attributed to an 
increase in cell proliferation, as AM did not stimulate 
rEC [3Hl -thymidine incorporation over the experimen- 
tal conditions examined. As a further extension of 
their original observations, Kat0 et al. (1997) have 
determined that rEC express a single population of 
AM receptor (Kd = 77 nM) with a calculated receptor 
density of 480,000 sites per cell. Nutritionally stressed 
rEC were shown to produce/release endogenous AM 
into the serum-free conditioned medium and expressed 
the 1.6 kb AM message. As a final experimental 
exercise to this study, Kat0 et al. (1997) evaluated 
rabbit anti-AM polyclonal antisera, in which exposure 
to  1.0% preimmune serum prevented the apoptotic 
event whereas immune serum, at the same concentra- 
tion, abrogated this protection, implicating an auto- 
crine/paracrine role for endogenous AM in suppressing 
programmed cell death. 
Adrenomedullin in Carcinogenesis 
Based on its initial isolation from a human 
pheochromocytoma tumor (Kitamura et al., 1993a1, 
there has always been an inherent relationship of AM 
with cancerous tissue. We have previously discussed 
the findings from our laboratory and collaborators 
that identify W A M - R  expression in pulmonary 
tumors, cervicaltovarian carcinomas, and in a variety 
of human tumor cell lines of diverse tissue origin 
(Martinez et al., 1995, 1997b; Miller et al., 1996; 
Macri et al., 1998). Additionally, we have demon- 
strated the potential for AM mediated autocrine 
growth of lung, breast, ovary, skin, and glioma tumor 
cells (Miller et al., 1996; Martinez et al., 1997a; 
Moody et al., 1997). Several other laboratories have 
identified AM expression in human colorectal carci- 
noma cells, human leukemia cell lines, adrenal 
tumors, ganglioneuroblastomas, neuroblastomas, and 
glial cell tumors (Satoh et al., 1995, 1997; Takahashi 
et al., 1997; Kubo et al. 1998a; Nakayama et al., 
1998). Consistent with these collective findings is the 
report by Ehlenz et al. (1997), who observed elevated 
AM levels in the plasma of patients with lung and 
gastrointestinal cancers. 
Recent studies by Wang, Peters, and Taparowsky 
from Purdue University have identified the possibility 
of oncogene regulated AM expression in transformed 
cells (Wang et al., 1996a,b; Peters et al., 1997). When 
comparing a rat fibroblast line (10T1/2) to  a v-myc 
transfected derivative ( myc neo 13A) by PCR-based 
mRNA differential display technique, these investiga- 
tors found that AM mRNA was down-regulated in the 
v-myc overexpressing line. Northern blot analysis 
using full length rat AM mRNA probes confirmed the 
expression of AM message in 10T1/2, whereas in the 
myc neo 13A it was lacking. Using an AM promoter/ 
luciferase reporter gene construct, it  was shown that a 
cis-acting DNA element in the AM promoter was 
responsible for v-myc down-regulation of AM expres- 
sion. These investigators have also discovered that 
transfecting 10T1/2 with other transforming on- 
cogenes (H-rus or E1A) could down-regulate AM 
expression. Interestingly, in dual transfected cells, the 
constitutive expression of AM could partially inhibit 
H-rus driven cellular transformation. Oncogene sup- 
pression of AM expression may underlie the hyper- 
proliferative state of tumor cells (see AM mediated 
growth suppression section of this text). 
One of the most interesting findings regarding AM/ 
tumor cell relationships is the recently discovered fact 
that both AM and its gene-related peptide (PAMP) 
inhibit the proliferation of human neuroblastoma cells 
(Ando et al., 1997). Ando et al. (1997) demonstrated 
that these peptides induced growth inhibition via 
separated receptors. CGRPg-37 and A M 2 2 - 5 2  blocked 
AM suppression of cell growth but did not affect 
PAMP activity. In addition, pertussis toxin and w- 
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conotoxin GIVA blocked the effect of PAMP but not 
that of AM. These collective data indicate that PAMP 
inhibits the growth of neuroblastoma cells by sup- 
pressing N-type Ca2+ channels through a pertussis 
toxin-sensitive G protein-coupled receptor and that 
AM growth suppression is mediated through a differ- 
ent receptorlsignal transduction pathway. 
Adrenomedullin in Wound Repair 
We have previously discussed the ability of AM to 
regulate growth (stimulate/suppress) and modulate 
angiogenesis; these complementary biological events 
are critical for wound repair. There have been two 
recent reports that support M A M - R  expression and 
interaction as being important in the repair of salt or 
ethanol induced gastric mucosa damage (Fukuda et 
al., 1998; Wang et al., 1998). Prior studies have 
identified the stomach as being an anatomical site for 
AM expression (Washimine et al., 1995; Mulder et al., 
1996). In addition, there are some reports that show 
peptidelreceptor segregation in the stomach, where a 
discrete population of cells at the neck of the gastric 
gland express AM, whereas the chief cells (bottom of 
the gland) have abundant AM-R message (Martinez 
et al., 1996a; Tomikawa et al., 1998). Fukuda et al. 
( 1998) demonstrated that AM promotes the epithelial 
restitution of rat and human gastric mucosa in vitro. 
These investigators have used isolated mucosal strips 
from the fundic gland area, placed in a Ussing 
chamber, to measure AM mediated recovery of the 
gastric mucosa to hyperosmolar shock treatments. The 
degree of salt induced damage was assessed by 
measuring the decrease in potential difference ( PD), 
short circuit current ( Isc) , and mucosal resistance 
(Rt ) .  Preexposure of test tissue (rat  or human) to 
AM prior to  salt damage ( . 5  M NaC1) resulted in 
truncated recovery times for PD, Isc, and Rt  to return 
to  normal levels, implicating AM as an enhancer of 
mucosal repair to  mild hyperosmolar shock. Studies by 
Wang et al. (1998) have examined phenotypic shifts 
in the intensity of W A M - R  expression at the 
periphery of necrotic zones triggered by ethanol 
induced damage to the gastric mucosa. Their data 
suggest that W A M - R  levels increase at proliferative 
epithelial borders that surround the necrotic lesion 
during the repair process, and suggest that these 
events play a critical role in the wound healing 
mechanism of the gut. 
In our extensive analysis of M A M - R  expression in 
the lung, we have shown that the ciliated columnar 
cells of the bronchfironchioli have dense apical 
immunostaining for the peptide ligand and positive in 
situ RT-PCR for AM mRNA, while being devoid of AM- 
R message (Martinez et al., 1995, 199713). Conversely, 
the progenitor cells (basal cells) of the pulmonary 
epithelium are lacking in AM expression, however, 
have high AM-R expression (Martinez et al., 199713). 
Thus, in the lung there appears to  be a clear 
anatomical segregation of W A M - R  expression be- 
tween differentiated and undifferentiated pulmonary 
epithelial cells. We have proposed that this physical 
separation between cell types may involve paracrine 
modes of action during wound repair. Because AM 
producing cells line the upper airway and this peptide 
appears to  be released into luminal spaces along 
mucosal surfaces, it is assumed that bronchial secre- 
tions would be laden with AM similar to what has 
been observed for lactating mammary epithelial ducts 
(Jahnke et al., 1997). Thus if pulmonary damage 
occurs (infection, chemical, or physical injury) and 
injured outer epithelial surfaces are sloughed, expos- 
ing underlying progenitor cells, the surrounding 
microenvironment would constitute an ideal medium 
to drive the repair process given the mitogenid 
angiogenic capabilities of AM. As healing continues 
and the basal cells are once again separated from 
outer mucosal surfaces due to cellular differentiation, 
AM availability would be suppressed and growth 
terminated. This hypothetical mechanism of normal 
pulmonary wound repair could also drive carcinogene- 
sis, as transformed pulmonary cells express both AM 
and AM-R (Miller et al., 1996). Thus, once the 
physical separation of M A M - R  breaks down and this 
theoretical internal control mechanism of the lung is 
disrupted, constitutive growth of cancer cells could 
occur. Further investigations are required to validate 
this proposed possibility underlying lung repair and 
carcinogenesis, which could have therapeutic implica- 
tions in defining new strategies against cancer and 
degenerative pulmonary diseases. 
We have recently shown that TGF-P1 and AM are 
coordinately expressed during rodent embryogenesis 
(Montuenga et al., 1998). Both TGF-P1 and AM are 
known to  play a critical role in growth, angiogenesis 
and differentiation (Roberts, et al., 1986; Miller et al., 
1998; Montuenga et al., 1998). Work published by 
Kane et al. (1991) has demonstrated the spatial/ 
temporal expression of TGF-P1 in cutaneous wound 
healing. They have shown, through selective im- 
munostaining techniques, that normal skin has abun- 
dant amounts of TGF-01 intracellularly expressed 
(inactive type) which is enzymatically altered to a 
modified state (active form) by a IeupeptidEDTA 
sensitive protease during the wound repair process. 
Kane and coworkers ( 19 9 1) have determined that 
active TGF-01 is rapidly produced at the injury site, 
shows up early in basal keratinocytes, but later is 
suppressed in these cells and found in blood vessels 
and papillary dermis, highly expressed at  the leading 
edge of the migrating epithelial sheet, and finally is 
shut off as the wound healing response is resolved. 
They propose that active TGF-P1 drives chemotaxis, 
proliferation, and differentiation during the wound 
repair process. We have recently reported the skin to  
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contain high amounts of M A M - R ,  which we believe 
play an important role in repair of injury and 
suppression of bacterial infection (Martinez et al., 
1997a). Given that TGF-01 and AM are coordinately 
expressed during fetal development, it will be interest- 
ing to determine whether a similar relationship is 
observed for AMPTGFq31 expression in the skin while 
cutaneous wound repair occurs. 
Adrenomedullin as an 
Antimicrobial Peptide 
When reviewing the collective information 
presented in this text, it becomes apparent that AM is 
a ubiquitous peptide found throughout all major 
epithelial surfaces (integument, respiratory, alimen- 
tary, and genitourinary tracts) and associated with 
activated macrophages (Martinez et al., 1995; Zhao et 
al., 1998), which implicates it as a possible an- 
timicrobial peptide similar to magainins, tracheal 
antimicrobial peptide ( TAP) and lingual an- 
timicrobial peptide ( LAP) (Zasloff, 1987; Diamond et 
al., 1991; Schonwetter et al., 1995). There is an 
enormous amount of investigative data in the litera- 
ture to  support this line of thought, which identifies 
AM as an acute response peptide to  bacterial invasion 
or endotoxic shock. Earlier reports by Sugo et al. 
(1994b, 1995) revealed that lipopolysaccharide 
( LPS), IL-1, and TNF-dNF-0 ,  biological entities 
associated with heighten immune response, could 
actively induce AM expression in rat VSMC. Similar 
LPS/IL-l/TNF mediated AM expression has been 
observed for rat endothelial cells (Isumi et al., 
1998b). Recent studies by Kubo and coworkers (Kubo 
et al., 1998a,b) have shown that LPS can stimulate 
the expression of AM in peritoneal macrophages and 
macrophage cell lines. In addition, they have demon- 
strated that in the absence of endotoxin, AM stimu- 
lates TNF-a expression in the murine macrophage cell 
line RAW 264.7. Conversely, AM introduced at  1 ph4 
concentration dramatically suppresses LPS-induced 
TNF-a production in this line (Kubo et al., 199813). 
These seminal studies by Kubo et al. suggest the 
possibility of AM acting as an autocrine regulator of 
the immune response mechanism. Very similar find- 
ings have been reported by Zaks-Zilberman et al. 
( 1998), which independently confirm the initial obser- 
vations by Kubo's group. Their studies also showed 
that the antitumor agent paclitaxel (Taxol) could 
increase AM production in peritoneal macrophages 
from the LPS responsive mouse strain, C3WOuJ, but 
not macrophages taken from the LPS hyporesponsive 
( L p s  mutant) mouse strain, C3WHeJ. In addition, 
they found that AM levels were increased in macro- 
phages taken from both mice strains when exposed to 
soluble Toxoplasma gondii tachyzoite antigen or the 
synthetic antitumor agent 5,6-dimethylxanthenone- 
$-acetic acid ( a  flavone analog). When protein synthe- 
sis of C3WOuJ macrophages was blocked with cyclo- 
heximide, Zaks-Zilberman et al. (1998) found that the 
basal level of AM mRNA was increased indicating the 
normal existence of a suppressor molecule, which 
down-regulates the steady-state expression of AM 
message. In the experimental rat model, intravenous 
injections of bacterial endotoxin resulted in augmenta- 
tion of AM plasma levels and increased AM mRNA 
expression in liver, heart, aorta, ileum, and kidney 
(Shoji et al., 1995; So et al., 1996). Along these same 
lines, clinical assessment of septic shock patients 
revealed AM plasma concentrations which were 10 to 
15 times higher than normal controls and AM urine 
levels were elevated in children with urinary tract 
infections (Hirata et al., 1996; Nishio et al., 1997; 
Dotsch et al., 1998). Given the cumulated evidence 
regarding AM responses to  bacterial endotoxin in 
laboratory animals and humans, it becomes increas- 
ingly evident that this peptide may encompass some 
type of host protection against microbial pathogens. 
We have demonstrated that AM and its gene 
related peptide, proadrenomedullin N-terminal 20 
peptide (PAMP), can function as antimicrobial pep- 
tides with defensin-like qualities capable of suppress- 
ing the growth of Escherichia coli and Candida 
albicans (Walsh et al., 1996, 1998). Both peptides 
showed a concentration- and time-dependent inhibi- 
tion of growth (direct killing effect) for these oppor- 
tunistic human pathogens using either a microdilution 
or macrodilution assay. Germination of C. albicans 
was also inhibited by these peptides. It was deter- 
mined that peptide fragments of either AM or PAMP 
showed drastically reduced ability to  suppress 
microbial growth, thus demonstrating the critical 
importance of intact molecules for host protection. 
BiochemicaVstructural analysis of AM and PAMP has 
shown these peptides to be highly charged (respective 
PI of 9.7 and 11.1) with extensive amphipathic 
regions that permit membrane intercalation leading to 
pore formation similar to  other antimicrobial peptides 
such as magainins, cecropins, and melittin 
(Bechinger, 1997). The ability of AM and PAMP to 
form ion-channels (membrane pores) in E. coli and C. 
albicans was determined first by fluorescent probe 
permeability assay and secondly by measuring cation 
eMux with atomic absorption spectroscopy. Once 
membrane integrity is disrupted and selective permea- 
bility lost, the effected pathogens are rapidly lysed in 
this hostile environment. 
There are indeed several interesting aspects of AM 
to  consider when contemplating its potential role in 
host protection: 1 ) the up-regulation of AM expression 
in response to endotoxin and proinflammatory 
cytokines. 2 ) Its inherent capacity to  auto-regulate 
the immune response mechanism either through a 
positive influence like recruitment of inactivated 
macrophages or through a negative influence by 
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Figure 2. The involvement of adrenomedullin (AM) in 
maintaining a dynamic balance in growth regulatory 
pathways in which it can function either as a stimulator 
or an inhibitor of cell replication. 
suppressing activated macrophage responses. 3 ) AM’s 
antimicrobial action, which can cause direct lysis of 
certain microbial pathogens. 4 )  The ability of AM to 
drive the repair process of damaged tissue via its 
mitogenic and angiogenic characteristics. The pursuit 
and exploitation of these biological attributes may 
prove to be of immense value in the clinical setting. 
Conclusion 
In this paper, we have tried to give a general 
overview of AM’s involvement in diverse physiological 
pathways as it relates to growth regulation. This 
peptide has been shown to be a highly conserved 
evolutionary molecule with origins dating back 100 
million yr or more and therefore assumed to play a 
critical role in species survival. Although at first 
glance the AM field may appear somewhat esoteric, 
since its first introduction into the literature in 1993 
by Kitamura et al. there have been over 600 publica- 
tions written, two international symposia held and a 
comprehensive book released on this topic. This 
peptide has stimulated the interest of the multidis- 
ciplinary scientific community and global coverage 
regarding its investigative studies is increasing ex- 
ponentially. In Table 1, we have cited examples in the 
literature which support AM as a mediator of growth 
regulation and have indicated its role in embryogene- 
sis, wound repair, and carcinogenesis. Figure 2 
illustrates the involvement of AM’s complex biology in 
the maintenance of a dynamic balance associated with 
growth regulatory pathways. Adrenomedullin can 
have both a growth suppressive or growth prolifera- 
tive function depending on the target cell examined 
and the environmental conditions in which the test is 
run. There are a variety of cytokines in which similar 
relationships have been identified, e.g., the diametric 
action of TGF-01 in growth control, in which its end 
response (proliferativehppressive) is dependent on 
the in concert growth factor repertoire of the target 
cell and the receptor subtype availability (Roberts et 
al., 1985; Majack, 1987; Goodman and Majack, 1989). 
As we rapidly approach the beginning of a new 
century and questions on the role of AM in growth 
regulation are addressed, it is predicted that this 
information will have a pivotal influence on clinical 
medicine and animal science as we know it today. 
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